 教育经历：
 2019-9至2022-6，南京中医药大学 博士
 2005-9至2008-7，协和医科大学 硕士
 2001-9至2005-7，山西医科大学 学士
 工作经历：
 2023.12至今， 新葡的京集团350vip8888官网， 张翱课题组，副研究员
 2021-05至2023.12，新葡的京集团350vip8888官网， 张翱课题组，实验师
 2016-11至2021-04，中国科学院上海药物研究所，张翱课题组，高级工程师
 2010-09至2016-10，中国科学院上海药物研究所，张翱课题组，助理研究员
 2008-08至2010-08，中国科学院上海药物研究所，张翱课题组，研究助理

基于肿瘤驱动基因、肿瘤微环境、免疫相关重要蛋白的抗肿瘤药物发现研究

1. Chen, M., Lei, S., Zhou, Z., Wang, M., Feng, C., Gao, X., Ding, C., Song, Z.*, Tang, W. *, Zhang, A*. (2024). Design, Synthesis, and Pharmacological Evaluation of Spiro[carbazole-3,3'-pyrrolidine] Derivatives as cGAS Inhibitors for Treatment of Acute Lung Injury. J. Med. Chem. 2024, 67(8), 6268–6291.
2. Zeng, R., Fang, M., Shen, A., Chai, X., Zhao, Y., Liu, M., Zhu, L., Rui, W., Feng, B., Hong, L., Ding, C., Song, Z. *, Lu, W. *, & Zhang, A*. (2024). Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD). J. Med. Chem. 2024, 67(5), 3520–3541.
3. Xie, C. 1, Liu, B. 1, Song, Z. 1, Yang, Y. 1, Dai, M., Gao, Y., Yao, Y., Ding, C., Ai, J., Zhang, A.. Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors. J. Med. Chem. 2023, 66, 16201–16221.
4. Song, Z. 1; Liu, B. 1; Peng, X.; Gu, W.; Sun, Y.; Xing, L.; Xu, Y.; Geng, M.; Ai, J.;* Zhang, A.* Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage. J. Med. Chem. 2021, 64, 16687-16702.
5. Song, Z. 1; Wang, X. 1; Zhang, Y. 1; Gu, W.; Shen, A.; Ding, C.; Li, H.; Xiao, R.; Geng, M.; Xie, Z.;* Zhang, A.* Structure-activity relationship study of amidobenzimidazole analogues leading to potent and systemically administrable STING agonists. J. Med. Chem. 2021, 64, 1649-1669.
6. Song Z. 1; Liu Y. 1; Xie C. 1; Tong X.; Wang X.; Zhou Y.; Gu W.; Zuo J.; He S.; Zhang A. Synthesis and pharmacological evaluation of choroquine derivatives bearing long aminated side chains as antivirus and anti-inflammatory agents. Bioorg. Chem. 2021, 116, 105346.
7. Xue, Y. 1; Song, P. 1; Song, Z.1; Wang, A.; Tong, L.; Geng, M. Y.; Ding, J.; Liu, Q.; Sun, L.; Xie, H.; Zhang, A. Discovery of 4,7-diamino-5-(4-phenoxyphenyl) -6-methylene-pyrimido[5,4-b]pyrrolizines as novel Bruton's tyrosine kinase (BTK) inhibitors. J. Med. Chem. 2018, 61, 4608-4627.
8. Song Z.1, Yang Y.1, Liu Z., Peng X., Guo J., Yang X., Kui Wu, Jing Ai, Jian Ding, Meiyu Geng, and Ao Zhang：Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases. J. Med. Chem. 2015, 58, 197–211.
9. Song Z., Wang M., Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm. Sinica B. 2015, 5, 34-37.
10. Song Z.1; Xia Z. 1; Ji Y.; Xing L.; Gao Y.; Ai J.; Geng M.; Zhang A. An Orally Available Tyrosine Kinase ALK and RET Dual Inhibitor Bearing the Tetracyclic Benzo[b]carbazolone Core. Eur. J. Med. Chem. 2016, 118, 244-249.
11. Wang Y., Xing L., Ji Y., Ye J., Dai Y., Gu W., Ai J. *, Song Z. *. Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1Hbenzo[d]azepin-7-yl)amino)pyrazine core. Bioorg. Med. Chem. Lett. 2019, 29(6): 836-838.
12. Wei M., Peng X., Xing L., Dai Y., Huang R., Geng M., Zhang A., Ai J.*, Song Z.* Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors. Eur. J. Med. Chem. 2018, 154, 9-28.
13. Geng K., Xia Z., Ji Y., Zhang R., Sun D., Ai J.*, Song Z.*, Geng M., Zhang A. Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. Eur. J. Med. Chem. 2018, 144, 386-397.

1． 作为药化负责人设计并合成了课题组研发的同时靶向肿瘤生长及微环境的1.1类新药盐酸希美替尼，2019年获得临床试验通知书（CXHL1800188、CXHL1800189），目前处于临床III期研究。已实现成果转换，转让合同金额：1.3亿元人民币；
2． 作为药化负责人设计并合成了课题组研发靶向BCR信号通路BTK抑制剂1.1类新药哌咯鲁替尼，2021年5月获得临床试验通知书（通知书编号：2021LP00699）。已实现成果转换，转让合同金额：0.86亿元人民币。